2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Pratibha Binder, MD, discusses key trials improving the array of treatment options for patients with endometrial cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Pratibha Binder, MD, gynecologic oncologist, assistant professor of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, UC San Diego Health, discusses key trials improving the array of treatment options for patients with endometrial cancer.
Treatment options for patients with endometrial cancer were previously limited to chemotherapy, radiation, and endocrine therapy, Binder states. In the past 5 years several trials have shifted this treatment paradigm to incorporate more effective alternatives, such as single-agent checkpoint inhibitors and combination treatments, Binder continues.
Notably, these trials also showed that such treatments did not have to be reserved for later lines. Instead, patients are now able to receive effective treatment immediately after first recurrence or failure of first-line chemotherapy, Binder concludes.
Related Content: